nodes	percent_of_prediction	percent_of_DWPC	metapath
Dinoprostone—SLCO1A2—Chlorambucil—ovarian cancer	0.23	0.558	CbGbCtD
Dinoprostone—CYP19A1—Paclitaxel—ovarian cancer	0.101	0.245	CbGbCtD
Dinoprostone—SLC22A7—Docetaxel—ovarian cancer	0.0813	0.197	CbGbCtD
Dinoprostone—PTGFR—corpus luteum—ovarian cancer	0.021	0.0784	CbGeAlD
Dinoprostone—CYP19A1—follicular fluid—ovarian cancer	0.018	0.0673	CbGeAlD
Dinoprostone—PTGFR—ovarian follicle—ovarian cancer	0.0164	0.0613	CbGeAlD
Dinoprostone—CYP11A1—corpus luteum—ovarian cancer	0.016	0.0597	CbGeAlD
Dinoprostone—CYP11A1—ovarian follicle—ovarian cancer	0.0125	0.0467	CbGeAlD
Dinoprostone—CYP19A1—corpus luteum—ovarian cancer	0.0104	0.0388	CbGeAlD
Dinoprostone—CYP19A1—ovarian follicle—ovarian cancer	0.00812	0.0303	CbGeAlD
Dinoprostone—PTGER2—myometrium—ovarian cancer	0.00347	0.013	CbGeAlD
Dinoprostone—SLC51B—endometrium—ovarian cancer	0.00328	0.0123	CbGeAlD
Dinoprostone—PTGER3—myometrium—ovarian cancer	0.00288	0.0108	CbGeAlD
Dinoprostone—PTGER2—uterine cervix—ovarian cancer	0.0027	0.0101	CbGeAlD
Dinoprostone—PTGER4—epithelium—ovarian cancer	0.00267	0.00999	CbGeAlD
Dinoprostone—PTGER2—decidua—ovarian cancer	0.00257	0.00961	CbGeAlD
Dinoprostone—PTGER4—decidua—ovarian cancer	0.00252	0.00943	CbGeAlD
Dinoprostone—HPGDS—myometrium—ovarian cancer	0.00249	0.00931	CbGeAlD
Dinoprostone—PTGER2—endometrium—ovarian cancer	0.00244	0.00912	CbGeAlD
Dinoprostone—HPGDS—embryo—ovarian cancer	0.0024	0.00896	CbGeAlD
Dinoprostone—PTGER4—endometrium—ovarian cancer	0.0024	0.00896	CbGeAlD
Dinoprostone—PTGFR—myometrium—ovarian cancer	0.0023	0.00861	CbGeAlD
Dinoprostone—PTGER2—uterus—ovarian cancer	0.00225	0.00841	CbGeAlD
Dinoprostone—PTGER4—uterus—ovarian cancer	0.00221	0.00825	CbGeAlD
Dinoprostone—SLC51B—testis—ovarian cancer	0.0022	0.00821	CbGeAlD
Dinoprostone—SLC51A—gonad—ovarian cancer	0.00218	0.00816	CbGeAlD
Dinoprostone—PTGER2—female reproductive system—ovarian cancer	0.00202	0.00756	CbGeAlD
Dinoprostone—PTGER4—female reproductive system—ovarian cancer	0.00198	0.00742	CbGeAlD
Dinoprostone—HPGDS—epithelium—ovarian cancer	0.00196	0.00731	CbGeAlD
Dinoprostone—SLC51A—female reproductive system—ovarian cancer	0.00195	0.00729	CbGeAlD
Dinoprostone—HPGDS—uterine cervix—ovarian cancer	0.00194	0.00725	CbGeAlD
Dinoprostone—PTGER1—female reproductive system—ovarian cancer	0.00192	0.00717	CbGeAlD
Dinoprostone—PTGER2—bone marrow—ovarian cancer	0.00191	0.00714	CbGeAlD
Dinoprostone—PTGER3—uterus—ovarian cancer	0.00187	0.00699	CbGeAlD
Dinoprostone—HPGDS—decidua—ovarian cancer	0.00185	0.00691	CbGeAlD
Dinoprostone—PTGER2—female gonad—ovarian cancer	0.00184	0.00688	CbGeAlD
Dinoprostone—PTGER2—vagina—ovarian cancer	0.00183	0.00684	CbGeAlD
Dinoprostone—PTGER4—female gonad—ovarian cancer	0.00181	0.00675	CbGeAlD
Dinoprostone—SLCO3A1—myometrium—ovarian cancer	0.00179	0.0067	CbGeAlD
Dinoprostone—SLCO2A1—myometrium—ovarian cancer	0.00178	0.00664	CbGeAlD
Dinoprostone—SLC51A—vagina—ovarian cancer	0.00176	0.00659	CbGeAlD
Dinoprostone—HPGDS—endometrium—ovarian cancer	0.00175	0.00655	CbGeAlD
Dinoprostone—PTGER1—female gonad—ovarian cancer	0.00174	0.00652	CbGeAlD
Dinoprostone—PTGER3—female reproductive system—ovarian cancer	0.00168	0.00628	CbGeAlD
Dinoprostone—SLCO4A1—myometrium—ovarian cancer	0.00163	0.0061	CbGeAlD
Dinoprostone—PTGER2—testis—ovarian cancer	0.00163	0.0061	CbGeAlD
Dinoprostone—HPGDS—gonad—ovarian cancer	0.00163	0.00608	CbGeAlD
Dinoprostone—HPGDS—uterus—ovarian cancer	0.00162	0.00604	CbGeAlD
Dinoprostone—PTGER4—testis—ovarian cancer	0.0016	0.00599	CbGeAlD
Dinoprostone—PTGIR—epithelium—ovarian cancer	0.00159	0.00596	CbGeAlD
Dinoprostone—SLC51A—testis—ovarian cancer	0.00157	0.00588	CbGeAlD
Dinoprostone—PTGER3—female gonad—ovarian cancer	0.00153	0.00572	CbGeAlD
Dinoprostone—PTGFR—uterus—ovarian cancer	0.00149	0.00559	CbGeAlD
Dinoprostone—HPGDS—female reproductive system—ovarian cancer	0.00145	0.00543	CbGeAlD
Dinoprostone—SLCO3A1—uterine cervix—ovarian cancer	0.0014	0.00521	CbGeAlD
Dinoprostone—SLCO2A1—epithelium—ovarian cancer	0.00139	0.00521	CbGeAlD
Dinoprostone—SLCO2A1—uterine cervix—ovarian cancer	0.00138	0.00516	CbGeAlD
Dinoprostone—HPGDS—bone marrow—ovarian cancer	0.00137	0.00513	CbGeAlD
Dinoprostone—PTGER3—testis—ovarian cancer	0.00136	0.00507	CbGeAlD
Dinoprostone—PTGFR—female reproductive system—ovarian cancer	0.00134	0.00502	CbGeAlD
Dinoprostone—PTGIR—gonad—ovarian cancer	0.00133	0.00496	CbGeAlD
Dinoprostone—HPGDS—female gonad—ovarian cancer	0.00132	0.00494	CbGeAlD
Dinoprostone—SLCO2A1—decidua—ovarian cancer	0.00132	0.00492	CbGeAlD
Dinoprostone—HPGDS—vagina—ovarian cancer	0.00131	0.00491	CbGeAlD
Dinoprostone—CYP11A1—decidua—ovarian cancer	0.0013	0.00487	CbGeAlD
Dinoprostone—ABCC5—uterine cervix—ovarian cancer	0.00126	0.00472	CbGeAlD
Dinoprostone—SLCO2A1—endometrium—ovarian cancer	0.00125	0.00467	CbGeAlD
Dinoprostone—PTGFR—female gonad—ovarian cancer	0.00122	0.00457	CbGeAlD
Dinoprostone—SLCO4A1—decidua—ovarian cancer	0.00121	0.00453	CbGeAlD
Dinoprostone—ABCC5—decidua—ovarian cancer	0.0012	0.0045	CbGeAlD
Dinoprostone—PTGIR—female reproductive system—ovarian cancer	0.00118	0.00443	CbGeAlD
Dinoprostone—PTGER2—lymph node—ovarian cancer	0.00118	0.00442	CbGeAlD
Dinoprostone—HPGDS—testis—ovarian cancer	0.00117	0.00438	CbGeAlD
Dinoprostone—SLCO3A1—gonad—ovarian cancer	0.00117	0.00437	CbGeAlD
Dinoprostone—PTGER4—lymph node—ovarian cancer	0.00116	0.00434	CbGeAlD
Dinoprostone—SLC22A11—female reproductive system—ovarian cancer	0.00115	0.00431	CbGeAlD
Dinoprostone—SLCO2A1—uterus—ovarian cancer	0.00115	0.0043	CbGeAlD
Dinoprostone—SLCO4A1—endometrium—ovarian cancer	0.00115	0.0043	CbGeAlD
Dinoprostone—CYP11A1—gonad—ovarian cancer	0.00115	0.00429	CbGeAlD
Dinoprostone—SLC51A—lymph node—ovarian cancer	0.00114	0.00426	CbGeAlD
Dinoprostone—PTGFR—testis—ovarian cancer	0.00108	0.00405	CbGeAlD
Dinoprostone—PTGIR—female gonad—ovarian cancer	0.00108	0.00403	CbGeAlD
Dinoprostone—SLCO3A1—female reproductive system—ovarian cancer	0.00105	0.00391	CbGeAlD
Dinoprostone—SLCO2A1—female reproductive system—ovarian cancer	0.00104	0.00387	CbGeAlD
Dinoprostone—CYP11A1—female reproductive system—ovarian cancer	0.00102	0.00383	CbGeAlD
Dinoprostone—PTGER3—lymph node—ovarian cancer	0.000983	0.00368	CbGeAlD
Dinoprostone—SLCO1C1—testis—ovarian cancer	0.000959	0.00358	CbGeAlD
Dinoprostone—PTGIR—testis—ovarian cancer	0.000956	0.00357	CbGeAlD
Dinoprostone—SLCO4A1—female reproductive system—ovarian cancer	0.000952	0.00356	CbGeAlD
Dinoprostone—SLCO3A1—female gonad—ovarian cancer	0.000951	0.00355	CbGeAlD
Dinoprostone—SLCO3A1—vagina—ovarian cancer	0.000945	0.00353	CbGeAlD
Dinoprostone—SLCO2B1—decidua—ovarian cancer	0.000942	0.00352	CbGeAlD
Dinoprostone—SLCO2A1—female gonad—ovarian cancer	0.000942	0.00352	CbGeAlD
Dinoprostone—SLCO2A1—vagina—ovarian cancer	0.000936	0.0035	CbGeAlD
Dinoprostone—CYP11A1—female gonad—ovarian cancer	0.000932	0.00348	CbGeAlD
Dinoprostone—SLC22A7—testis—ovarian cancer	0.000909	0.0034	CbGeAlD
Dinoprostone—ABCC5—bone marrow—ovarian cancer	0.000894	0.00334	CbGeAlD
Dinoprostone—ABCC5—female gonad—ovarian cancer	0.000862	0.00322	CbGeAlD
Dinoprostone—SLCO4A1—vagina—ovarian cancer	0.000861	0.00322	CbGeAlD
Dinoprostone—ABCC5—vagina—ovarian cancer	0.000856	0.0032	CbGeAlD
Dinoprostone—HPGDS—lymph node—ovarian cancer	0.00085	0.00318	CbGeAlD
Dinoprostone—SLCO3A1—testis—ovarian cancer	0.000844	0.00315	CbGeAlD
Dinoprostone—SLCO1B1—female reproductive system—ovarian cancer	0.000838	0.00313	CbGeAlD
Dinoprostone—SLCO2A1—testis—ovarian cancer	0.000835	0.00312	CbGeAlD
Dinoprostone—CYP11A1—testis—ovarian cancer	0.000827	0.00309	CbGeAlD
Dinoprostone—SLCO2B1—uterus—ovarian cancer	0.000824	0.00308	CbGeAlD
Dinoprostone—CYP19A1—endometrium—ovarian cancer	0.000803	0.003	CbGeAlD
Dinoprostone—PTGFR—lymph node—ovarian cancer	0.000786	0.00294	CbGeAlD
Dinoprostone—SLCO4A1—testis—ovarian cancer	0.000769	0.00287	CbGeAlD
Dinoprostone—ABCC5—testis—ovarian cancer	0.000764	0.00286	CbGeAlD
Dinoprostone—CYP19A1—gonad—ovarian cancer	0.000745	0.00279	CbGeAlD
Dinoprostone—SLCO2B1—female reproductive system—ovarian cancer	0.000741	0.00277	CbGeAlD
Dinoprostone—CYP19A1—uterus—ovarian cancer	0.00074	0.00277	CbGeAlD
Dinoprostone—ABCC4—uterus—ovarian cancer	0.00073	0.00273	CbGeAlD
Dinoprostone—SLCO1C1—lymph node—ovarian cancer	0.000695	0.0026	CbGeAlD
Dinoprostone—PTGIR—lymph node—ovarian cancer	0.000693	0.00259	CbGeAlD
Dinoprostone—SLCO2B1—female gonad—ovarian cancer	0.000674	0.00252	CbGeAlD
Dinoprostone—CYP19A1—female reproductive system—ovarian cancer	0.000665	0.00249	CbGeAlD
Dinoprostone—ABCC4—female reproductive system—ovarian cancer	0.000656	0.00245	CbGeAlD
Dinoprostone—SLC22A1—vagina—ovarian cancer	0.00064	0.00239	CbGeAlD
Dinoprostone—Anaphylactic shock—Topotecan—ovarian cancer	0.000635	0.00413	CcSEcCtD
Dinoprostone—Sweating increased—Paclitaxel—ovarian cancer	0.000626	0.00407	CcSEcCtD
Dinoprostone—Anaphylactic shock—Melphalan—ovarian cancer	0.000622	0.00405	CcSEcCtD
Dinoprostone—ABCC4—bone marrow—ovarian cancer	0.00062	0.00232	CbGeAlD
Dinoprostone—Hyperhidrosis—Topotecan—ovarian cancer	0.000614	0.004	CcSEcCtD
Dinoprostone—SLCO3A1—lymph node—ovarian cancer	0.000611	0.00229	CbGeAlD
Dinoprostone—Pain—Chlorambucil—ovarian cancer	0.00061	0.00397	CcSEcCtD
Dinoprostone—Tachycardia—Melphalan—ovarian cancer	0.000607	0.00395	CcSEcCtD
Dinoprostone—SLCO2A1—lymph node—ovarian cancer	0.000606	0.00226	CbGeAlD
Dinoprostone—CYP19A1—female gonad—ovarian cancer	0.000606	0.00226	CbGeAlD
Dinoprostone—Inflammation—Epirubicin—ovarian cancer	0.000604	0.00393	CcSEcCtD
Dinoprostone—Skin discolouration—Doxorubicin—ovarian cancer	0.0006	0.0039	CcSEcCtD
Dinoprostone—CYP11A1—lymph node—ovarian cancer	0.000599	0.00224	CbGeAlD
Dinoprostone—SLCO2B1—testis—ovarian cancer	0.000598	0.00224	CbGeAlD
Dinoprostone—ABCC4—female gonad—ovarian cancer	0.000597	0.00223	CbGeAlD
Dinoprostone—Dehydration—Docetaxel—ovarian cancer	0.000586	0.00381	CcSEcCtD
Dinoprostone—Vaginal inflammation—Epirubicin—ovarian cancer	0.000586	0.00381	CcSEcCtD
Dinoprostone—Hiccups—Epirubicin—ovarian cancer	0.000586	0.00381	CcSEcCtD
Dinoprostone—Gastrointestinal pain—Chlorambucil—ovarian cancer	0.000583	0.0038	CcSEcCtD
Dinoprostone—Hypotension—Melphalan—ovarian cancer	0.000581	0.00378	CcSEcCtD
Dinoprostone—Cough—Vinorelbine—ovarian cancer	0.000581	0.00378	CcSEcCtD
Dinoprostone—Musculoskeletal discomfort—Topotecan—ovarian cancer	0.000579	0.00377	CcSEcCtD
Dinoprostone—Hypertension—Vinorelbine—ovarian cancer	0.000575	0.00374	CcSEcCtD
Dinoprostone—Paraesthesia—Topotecan—ovarian cancer	0.00057	0.00371	CcSEcCtD
Dinoprostone—Cramp muscle—Docetaxel—ovarian cancer	0.000567	0.00369	CcSEcCtD
Dinoprostone—Arthralgia—Vinorelbine—ovarian cancer	0.000567	0.00369	CcSEcCtD
Dinoprostone—Chest pain—Vinorelbine—ovarian cancer	0.000567	0.00369	CcSEcCtD
Dinoprostone—Myalgia—Vinorelbine—ovarian cancer	0.000567	0.00369	CcSEcCtD
Dinoprostone—Musculoskeletal discomfort—Melphalan—ovarian cancer	0.000566	0.00369	CcSEcCtD
Dinoprostone—Dyspnoea—Topotecan—ovarian cancer	0.000566	0.00369	CcSEcCtD
Dinoprostone—Acute coronary syndrome—Paclitaxel—ovarian cancer	0.000565	0.00368	CcSEcCtD
Dinoprostone—Abdominal pain—Chlorambucil—ovarian cancer	0.000564	0.00367	CcSEcCtD
Dinoprostone—Body temperature increased—Chlorambucil—ovarian cancer	0.000564	0.00367	CcSEcCtD
Dinoprostone—Myocardial infarction—Paclitaxel—ovarian cancer	0.000562	0.00366	CcSEcCtD
Dinoprostone—Inflammation—Doxorubicin—ovarian cancer	0.000559	0.00364	CcSEcCtD
Dinoprostone—Paraesthesia—Melphalan—ovarian cancer	0.000558	0.00363	CcSEcCtD
Dinoprostone—SLCO4A1—lymph node—ovarian cancer	0.000557	0.00208	CbGeAlD
Dinoprostone—Dyspnoea—Melphalan—ovarian cancer	0.000554	0.00361	CcSEcCtD
Dinoprostone—ABCC5—lymph node—ovarian cancer	0.000554	0.00207	CbGeAlD
Dinoprostone—Vaginal infection—Epirubicin—ovarian cancer	0.000553	0.0036	CcSEcCtD
Dinoprostone—SLCO1A2—testis—ovarian cancer	0.00055	0.00206	CbGeAlD
Dinoprostone—Anaphylactic shock—Vinorelbine—ovarian cancer	0.000543	0.00354	CcSEcCtD
Dinoprostone—Pain—Topotecan—ovarian cancer	0.000543	0.00354	CcSEcCtD
Dinoprostone—Hiccups—Doxorubicin—ovarian cancer	0.000542	0.00353	CcSEcCtD
Dinoprostone—Vaginal inflammation—Doxorubicin—ovarian cancer	0.000542	0.00353	CcSEcCtD
Dinoprostone—Cramps of lower extremities—Epirubicin—ovarian cancer	0.000538	0.0035	CcSEcCtD
Dinoprostone—CYP19A1—testis—ovarian cancer	0.000537	0.00201	CbGeAlD
Dinoprostone—Bronchospasm—Docetaxel—ovarian cancer	0.000536	0.00349	CcSEcCtD
Dinoprostone—Pain—Melphalan—ovarian cancer	0.000532	0.00346	CcSEcCtD
Dinoprostone—Tachycardia—Vinorelbine—ovarian cancer	0.00053	0.00345	CcSEcCtD
Dinoprostone—ABCC4—testis—ovarian cancer	0.00053	0.00198	CbGeAlD
Dinoprostone—Hypersensitivity—Chlorambucil—ovarian cancer	0.000526	0.00342	CcSEcCtD
Dinoprostone—Gastrointestinal pain—Topotecan—ovarian cancer	0.000519	0.00338	CcSEcCtD
Dinoprostone—Hypertonia—Epirubicin—ovarian cancer	0.000513	0.00334	CcSEcCtD
Dinoprostone—Asthenia—Chlorambucil—ovarian cancer	0.000512	0.00333	CcSEcCtD
Dinoprostone—Vaginal infection—Doxorubicin—ovarian cancer	0.000511	0.00333	CcSEcCtD
Dinoprostone—Pharyngitis—Paclitaxel—ovarian cancer	0.00051	0.00332	CcSEcCtD
Dinoprostone—Hypotension—Vinorelbine—ovarian cancer	0.000508	0.0033	CcSEcCtD
Dinoprostone—Abdominal pain—Topotecan—ovarian cancer	0.000502	0.00327	CcSEcCtD
Dinoprostone—Body temperature increased—Topotecan—ovarian cancer	0.000502	0.00327	CcSEcCtD
Dinoprostone—Cramps of lower extremities—Doxorubicin—ovarian cancer	0.000498	0.00324	CcSEcCtD
Dinoprostone—Musculoskeletal discomfort—Vinorelbine—ovarian cancer	0.000495	0.00322	CcSEcCtD
Dinoprostone—Diarrhoea—Chlorambucil—ovarian cancer	0.000488	0.00318	CcSEcCtD
Dinoprostone—Paraesthesia—Vinorelbine—ovarian cancer	0.000488	0.00318	CcSEcCtD
Dinoprostone—Dyspnoea—Vinorelbine—ovarian cancer	0.000484	0.00315	CcSEcCtD
Dinoprostone—Acute coronary syndrome—Docetaxel—ovarian cancer	0.000479	0.00312	CcSEcCtD
Dinoprostone—Flushing—Paclitaxel—ovarian cancer	0.000477	0.00311	CcSEcCtD
Dinoprostone—Myocardial infarction—Docetaxel—ovarian cancer	0.000476	0.0031	CcSEcCtD
Dinoprostone—Hypertonia—Doxorubicin—ovarian cancer	0.000475	0.00309	CcSEcCtD
Dinoprostone—Eye pain—Epirubicin—ovarian cancer	0.000471	0.00306	CcSEcCtD
Dinoprostone—Hypersensitivity—Topotecan—ovarian cancer	0.000468	0.00305	CcSEcCtD
Dinoprostone—Angiopathy—Paclitaxel—ovarian cancer	0.000467	0.00304	CcSEcCtD
Dinoprostone—Pain—Vinorelbine—ovarian cancer	0.000465	0.00302	CcSEcCtD
Dinoprostone—Immune system disorder—Paclitaxel—ovarian cancer	0.000465	0.00302	CcSEcCtD
Dinoprostone—Chills—Paclitaxel—ovarian cancer	0.000461	0.003	CcSEcCtD
Dinoprostone—Arrhythmia—Paclitaxel—ovarian cancer	0.000459	0.00299	CcSEcCtD
Dinoprostone—Hypersensitivity—Melphalan—ovarian cancer	0.000458	0.00298	CcSEcCtD
Dinoprostone—Asthenia—Topotecan—ovarian cancer	0.000456	0.00297	CcSEcCtD
Dinoprostone—Hot flush—Epirubicin—ovarian cancer	0.000454	0.00296	CcSEcCtD
Dinoprostone—Vomiting—Chlorambucil—ovarian cancer	0.000454	0.00295	CcSEcCtD
Dinoprostone—Menopausal symptoms—Epirubicin—ovarian cancer	0.00045	0.00293	CcSEcCtD
Dinoprostone—Asthenia—Melphalan—ovarian cancer	0.000446	0.0029	CcSEcCtD
Dinoprostone—Gastrointestinal pain—Vinorelbine—ovarian cancer	0.000444	0.00289	CcSEcCtD
Dinoprostone—Tension—Paclitaxel—ovarian cancer	0.000439	0.00286	CcSEcCtD
Dinoprostone—Anaphylactoid reaction—Epirubicin—ovarian cancer	0.000439	0.00286	CcSEcCtD
Dinoprostone—Eye pain—Doxorubicin—ovarian cancer	0.000436	0.00284	CcSEcCtD
Dinoprostone—Diarrhoea—Topotecan—ovarian cancer	0.000434	0.00283	CcSEcCtD
Dinoprostone—SLCO2B1—lymph node—ovarian cancer	0.000433	0.00162	CbGeAlD
Dinoprostone—Back pain—Paclitaxel—ovarian cancer	0.000433	0.00282	CcSEcCtD
Dinoprostone—Pharyngitis—Docetaxel—ovarian cancer	0.000433	0.00282	CcSEcCtD
Dinoprostone—Muscle spasms—Paclitaxel—ovarian cancer	0.00043	0.0028	CcSEcCtD
Dinoprostone—Abdominal pain—Vinorelbine—ovarian cancer	0.000429	0.0028	CcSEcCtD
Dinoprostone—Body temperature increased—Vinorelbine—ovarian cancer	0.000429	0.0028	CcSEcCtD
Dinoprostone—Diarrhoea—Melphalan—ovarian cancer	0.000425	0.00277	CcSEcCtD
Dinoprostone—Nausea—Chlorambucil—ovarian cancer	0.000424	0.00276	CcSEcCtD
Dinoprostone—Vision blurred—Paclitaxel—ovarian cancer	0.000422	0.00275	CcSEcCtD
Dinoprostone—Hot flush—Doxorubicin—ovarian cancer	0.00042	0.00274	CcSEcCtD
Dinoprostone—Dizziness—Topotecan—ovarian cancer	0.00042	0.00273	CcSEcCtD
Dinoprostone—Tremor—Paclitaxel—ovarian cancer	0.000419	0.00273	CcSEcCtD
Dinoprostone—Menopausal symptoms—Doxorubicin—ovarian cancer	0.000417	0.00271	CcSEcCtD
Dinoprostone—Anaphylactoid reaction—Doxorubicin—ovarian cancer	0.000406	0.00265	CcSEcCtD
Dinoprostone—Flushing—Docetaxel—ovarian cancer	0.000405	0.00263	CcSEcCtD
Dinoprostone—Cardiac arrest—Epirubicin—ovarian cancer	0.000404	0.00263	CcSEcCtD
Dinoprostone—Vomiting—Topotecan—ovarian cancer	0.000404	0.00263	CcSEcCtD
Dinoprostone—Syncope—Paclitaxel—ovarian cancer	0.000401	0.00261	CcSEcCtD
Dinoprostone—Rash—Topotecan—ovarian cancer	0.0004	0.00261	CcSEcCtD
Dinoprostone—Hypersensitivity—Vinorelbine—ovarian cancer	0.0004	0.00261	CcSEcCtD
Dinoprostone—Dermatitis—Topotecan—ovarian cancer	0.0004	0.0026	CcSEcCtD
Dinoprostone—Headache—Topotecan—ovarian cancer	0.000398	0.00259	CcSEcCtD
Dinoprostone—Angiopathy—Docetaxel—ovarian cancer	0.000395	0.00257	CcSEcCtD
Dinoprostone—Vomiting—Melphalan—ovarian cancer	0.000395	0.00257	CcSEcCtD
Dinoprostone—Dehydration—Epirubicin—ovarian cancer	0.000395	0.00257	CcSEcCtD
Dinoprostone—Immune system disorder—Docetaxel—ovarian cancer	0.000394	0.00256	CcSEcCtD
Dinoprostone—Loss of consciousness—Paclitaxel—ovarian cancer	0.000393	0.00256	CcSEcCtD
Dinoprostone—Rash—Melphalan—ovarian cancer	0.000392	0.00255	CcSEcCtD
Dinoprostone—Dermatitis—Melphalan—ovarian cancer	0.000392	0.00255	CcSEcCtD
Dinoprostone—Chills—Docetaxel—ovarian cancer	0.000391	0.00255	CcSEcCtD
Dinoprostone—Cough—Paclitaxel—ovarian cancer	0.000391	0.00254	CcSEcCtD
Dinoprostone—Asthenia—Vinorelbine—ovarian cancer	0.00039	0.00254	CcSEcCtD
Dinoprostone—Arrhythmia—Docetaxel—ovarian cancer	0.000389	0.00254	CcSEcCtD
Dinoprostone—CYP19A1—lymph node—ovarian cancer	0.000389	0.00146	CbGeAlD
Dinoprostone—Hypertension—Paclitaxel—ovarian cancer	0.000387	0.00252	CcSEcCtD
Dinoprostone—ABCC4—lymph node—ovarian cancer	0.000384	0.00143	CbGeAlD
Dinoprostone—Arthralgia—Paclitaxel—ovarian cancer	0.000381	0.00248	CcSEcCtD
Dinoprostone—Chest pain—Paclitaxel—ovarian cancer	0.000381	0.00248	CcSEcCtD
Dinoprostone—Myalgia—Paclitaxel—ovarian cancer	0.000381	0.00248	CcSEcCtD
Dinoprostone—Nausea—Topotecan—ovarian cancer	0.000377	0.00246	CcSEcCtD
Dinoprostone—Cardiac arrest—Doxorubicin—ovarian cancer	0.000374	0.00243	CcSEcCtD
Dinoprostone—Diarrhoea—Vinorelbine—ovarian cancer	0.000372	0.00242	CcSEcCtD
Dinoprostone—Nausea—Melphalan—ovarian cancer	0.000369	0.0024	CcSEcCtD
Dinoprostone—Asthma—Epirubicin—ovarian cancer	0.000367	0.00239	CcSEcCtD
Dinoprostone—Back pain—Docetaxel—ovarian cancer	0.000367	0.00239	CcSEcCtD
Dinoprostone—Dehydration—Doxorubicin—ovarian cancer	0.000366	0.00238	CcSEcCtD
Dinoprostone—Anaphylactic shock—Paclitaxel—ovarian cancer	0.000365	0.00238	CcSEcCtD
Dinoprostone—Muscle spasms—Docetaxel—ovarian cancer	0.000365	0.00238	CcSEcCtD
Dinoprostone—Shock—Paclitaxel—ovarian cancer	0.000359	0.00234	CcSEcCtD
Dinoprostone—Dizziness—Vinorelbine—ovarian cancer	0.000359	0.00234	CcSEcCtD
Dinoprostone—Tachycardia—Paclitaxel—ovarian cancer	0.000357	0.00232	CcSEcCtD
Dinoprostone—Hyperhidrosis—Paclitaxel—ovarian cancer	0.000353	0.0023	CcSEcCtD
Dinoprostone—Vomiting—Vinorelbine—ovarian cancer	0.000345	0.00225	CcSEcCtD
Dinoprostone—Rash—Vinorelbine—ovarian cancer	0.000343	0.00223	CcSEcCtD
Dinoprostone—Dermatitis—Vinorelbine—ovarian cancer	0.000342	0.00223	CcSEcCtD
Dinoprostone—Hypotension—Paclitaxel—ovarian cancer	0.000341	0.00222	CcSEcCtD
Dinoprostone—Headache—Vinorelbine—ovarian cancer	0.00034	0.00222	CcSEcCtD
Dinoprostone—Syncope—Docetaxel—ovarian cancer	0.00034	0.00222	CcSEcCtD
Dinoprostone—Asthma—Doxorubicin—ovarian cancer	0.00034	0.00221	CcSEcCtD
Dinoprostone—Loss of consciousness—Docetaxel—ovarian cancer	0.000334	0.00217	CcSEcCtD
Dinoprostone—Musculoskeletal discomfort—Paclitaxel—ovarian cancer	0.000333	0.00217	CcSEcCtD
Dinoprostone—Cough—Docetaxel—ovarian cancer	0.000331	0.00216	CcSEcCtD
Dinoprostone—Paraesthesia—Paclitaxel—ovarian cancer	0.000328	0.00214	CcSEcCtD
Dinoprostone—Hypertension—Docetaxel—ovarian cancer	0.000328	0.00213	CcSEcCtD
Dinoprostone—Dyspnoea—Paclitaxel—ovarian cancer	0.000326	0.00212	CcSEcCtD
Dinoprostone—Arthralgia—Docetaxel—ovarian cancer	0.000323	0.0021	CcSEcCtD
Dinoprostone—Chest pain—Docetaxel—ovarian cancer	0.000323	0.0021	CcSEcCtD
Dinoprostone—Myalgia—Docetaxel—ovarian cancer	0.000323	0.0021	CcSEcCtD
Dinoprostone—Nausea—Vinorelbine—ovarian cancer	0.000323	0.0021	CcSEcCtD
Dinoprostone—Pain—Paclitaxel—ovarian cancer	0.000312	0.00203	CcSEcCtD
Dinoprostone—Anaphylactic shock—Docetaxel—ovarian cancer	0.00031	0.00202	CcSEcCtD
Dinoprostone—Shock—Docetaxel—ovarian cancer	0.000305	0.00198	CcSEcCtD
Dinoprostone—Tachycardia—Docetaxel—ovarian cancer	0.000302	0.00197	CcSEcCtD
Dinoprostone—Gastrointestinal pain—Paclitaxel—ovarian cancer	0.000299	0.00195	CcSEcCtD
Dinoprostone—Pharyngitis—Epirubicin—ovarian cancer	0.000292	0.0019	CcSEcCtD
Dinoprostone—Hypotension—Docetaxel—ovarian cancer	0.000289	0.00188	CcSEcCtD
Dinoprostone—Body temperature increased—Paclitaxel—ovarian cancer	0.000289	0.00188	CcSEcCtD
Dinoprostone—Abdominal pain—Paclitaxel—ovarian cancer	0.000289	0.00188	CcSEcCtD
Dinoprostone—Musculoskeletal discomfort—Docetaxel—ovarian cancer	0.000282	0.00184	CcSEcCtD
Dinoprostone—Paraesthesia—Docetaxel—ovarian cancer	0.000278	0.00181	CcSEcCtD
Dinoprostone—Dyspnoea—Docetaxel—ovarian cancer	0.000276	0.0018	CcSEcCtD
Dinoprostone—Flushing—Epirubicin—ovarian cancer	0.000273	0.00178	CcSEcCtD
Dinoprostone—Pharyngitis—Doxorubicin—ovarian cancer	0.00027	0.00176	CcSEcCtD
Dinoprostone—Hypersensitivity—Paclitaxel—ovarian cancer	0.000269	0.00175	CcSEcCtD
Dinoprostone—Angiopathy—Epirubicin—ovarian cancer	0.000267	0.00174	CcSEcCtD
Dinoprostone—Immune system disorder—Epirubicin—ovarian cancer	0.000266	0.00173	CcSEcCtD
Dinoprostone—Pain—Docetaxel—ovarian cancer	0.000265	0.00172	CcSEcCtD
Dinoprostone—Chills—Epirubicin—ovarian cancer	0.000264	0.00172	CcSEcCtD
Dinoprostone—Arrhythmia—Epirubicin—ovarian cancer	0.000263	0.00171	CcSEcCtD
Dinoprostone—Asthenia—Paclitaxel—ovarian cancer	0.000262	0.00171	CcSEcCtD
Dinoprostone—Gastrointestinal pain—Docetaxel—ovarian cancer	0.000253	0.00165	CcSEcCtD
Dinoprostone—Flushing—Doxorubicin—ovarian cancer	0.000252	0.00164	CcSEcCtD
Dinoprostone—Tension—Epirubicin—ovarian cancer	0.000251	0.00164	CcSEcCtD
Dinoprostone—Diarrhoea—Paclitaxel—ovarian cancer	0.00025	0.00163	CcSEcCtD
Dinoprostone—Back pain—Epirubicin—ovarian cancer	0.000248	0.00161	CcSEcCtD
Dinoprostone—Angiopathy—Doxorubicin—ovarian cancer	0.000247	0.00161	CcSEcCtD
Dinoprostone—Muscle spasms—Epirubicin—ovarian cancer	0.000246	0.0016	CcSEcCtD
Dinoprostone—Immune system disorder—Doxorubicin—ovarian cancer	0.000246	0.0016	CcSEcCtD
Dinoprostone—Body temperature increased—Docetaxel—ovarian cancer	0.000245	0.00159	CcSEcCtD
Dinoprostone—Abdominal pain—Docetaxel—ovarian cancer	0.000245	0.00159	CcSEcCtD
Dinoprostone—Chills—Doxorubicin—ovarian cancer	0.000244	0.00159	CcSEcCtD
Dinoprostone—Arrhythmia—Doxorubicin—ovarian cancer	0.000243	0.00158	CcSEcCtD
Dinoprostone—Dizziness—Paclitaxel—ovarian cancer	0.000242	0.00157	CcSEcCtD
Dinoprostone—Vision blurred—Epirubicin—ovarian cancer	0.000241	0.00157	CcSEcCtD
Dinoprostone—Tension—Doxorubicin—ovarian cancer	0.000232	0.00151	CcSEcCtD
Dinoprostone—Vomiting—Paclitaxel—ovarian cancer	0.000232	0.00151	CcSEcCtD
Dinoprostone—Rash—Paclitaxel—ovarian cancer	0.00023	0.0015	CcSEcCtD
Dinoprostone—Dermatitis—Paclitaxel—ovarian cancer	0.00023	0.0015	CcSEcCtD
Dinoprostone—Syncope—Epirubicin—ovarian cancer	0.00023	0.00149	CcSEcCtD
Dinoprostone—Back pain—Doxorubicin—ovarian cancer	0.000229	0.00149	CcSEcCtD
Dinoprostone—Headache—Paclitaxel—ovarian cancer	0.000229	0.00149	CcSEcCtD
Dinoprostone—Hypersensitivity—Docetaxel—ovarian cancer	0.000228	0.00149	CcSEcCtD
Dinoprostone—Muscle spasms—Doxorubicin—ovarian cancer	0.000228	0.00148	CcSEcCtD
Dinoprostone—Loss of consciousness—Epirubicin—ovarian cancer	0.000225	0.00146	CcSEcCtD
Dinoprostone—Cough—Epirubicin—ovarian cancer	0.000223	0.00145	CcSEcCtD
Dinoprostone—Vision blurred—Doxorubicin—ovarian cancer	0.000223	0.00145	CcSEcCtD
Dinoprostone—Asthenia—Docetaxel—ovarian cancer	0.000222	0.00145	CcSEcCtD
Dinoprostone—Hypertension—Epirubicin—ovarian cancer	0.000221	0.00144	CcSEcCtD
Dinoprostone—Chest pain—Epirubicin—ovarian cancer	0.000218	0.00142	CcSEcCtD
Dinoprostone—Arthralgia—Epirubicin—ovarian cancer	0.000218	0.00142	CcSEcCtD
Dinoprostone—Myalgia—Epirubicin—ovarian cancer	0.000218	0.00142	CcSEcCtD
Dinoprostone—Nausea—Paclitaxel—ovarian cancer	0.000217	0.00141	CcSEcCtD
Dinoprostone—Syncope—Doxorubicin—ovarian cancer	0.000212	0.00138	CcSEcCtD
Dinoprostone—Diarrhoea—Docetaxel—ovarian cancer	0.000212	0.00138	CcSEcCtD
Dinoprostone—Anaphylactic shock—Epirubicin—ovarian cancer	0.000209	0.00136	CcSEcCtD
Dinoprostone—Loss of consciousness—Doxorubicin—ovarian cancer	0.000208	0.00136	CcSEcCtD
Dinoprostone—Cough—Doxorubicin—ovarian cancer	0.000207	0.00135	CcSEcCtD
Dinoprostone—Shock—Epirubicin—ovarian cancer	0.000206	0.00134	CcSEcCtD
Dinoprostone—Dizziness—Docetaxel—ovarian cancer	0.000205	0.00133	CcSEcCtD
Dinoprostone—Hypertension—Doxorubicin—ovarian cancer	0.000204	0.00133	CcSEcCtD
Dinoprostone—Tachycardia—Epirubicin—ovarian cancer	0.000204	0.00133	CcSEcCtD
Dinoprostone—Hyperhidrosis—Epirubicin—ovarian cancer	0.000202	0.00131	CcSEcCtD
Dinoprostone—Arthralgia—Doxorubicin—ovarian cancer	0.000202	0.00131	CcSEcCtD
Dinoprostone—Myalgia—Doxorubicin—ovarian cancer	0.000202	0.00131	CcSEcCtD
Dinoprostone—Chest pain—Doxorubicin—ovarian cancer	0.000202	0.00131	CcSEcCtD
Dinoprostone—Vomiting—Docetaxel—ovarian cancer	0.000197	0.00128	CcSEcCtD
Dinoprostone—Rash—Docetaxel—ovarian cancer	0.000195	0.00127	CcSEcCtD
Dinoprostone—Hypotension—Epirubicin—ovarian cancer	0.000195	0.00127	CcSEcCtD
Dinoprostone—Dermatitis—Docetaxel—ovarian cancer	0.000195	0.00127	CcSEcCtD
Dinoprostone—Headache—Docetaxel—ovarian cancer	0.000194	0.00126	CcSEcCtD
Dinoprostone—Anaphylactic shock—Doxorubicin—ovarian cancer	0.000193	0.00126	CcSEcCtD
Dinoprostone—Musculoskeletal discomfort—Epirubicin—ovarian cancer	0.00019	0.00124	CcSEcCtD
Dinoprostone—Shock—Doxorubicin—ovarian cancer	0.00019	0.00124	CcSEcCtD
Dinoprostone—Tachycardia—Doxorubicin—ovarian cancer	0.000189	0.00123	CcSEcCtD
Dinoprostone—Paraesthesia—Epirubicin—ovarian cancer	0.000188	0.00122	CcSEcCtD
Dinoprostone—Hyperhidrosis—Doxorubicin—ovarian cancer	0.000187	0.00122	CcSEcCtD
Dinoprostone—Dyspnoea—Epirubicin—ovarian cancer	0.000186	0.00121	CcSEcCtD
Dinoprostone—Nausea—Docetaxel—ovarian cancer	0.000184	0.0012	CcSEcCtD
Dinoprostone—Hypotension—Doxorubicin—ovarian cancer	0.000181	0.00118	CcSEcCtD
Dinoprostone—Pain—Epirubicin—ovarian cancer	0.000179	0.00116	CcSEcCtD
Dinoprostone—Musculoskeletal discomfort—Doxorubicin—ovarian cancer	0.000176	0.00115	CcSEcCtD
Dinoprostone—Paraesthesia—Doxorubicin—ovarian cancer	0.000174	0.00113	CcSEcCtD
Dinoprostone—Dyspnoea—Doxorubicin—ovarian cancer	0.000172	0.00112	CcSEcCtD
Dinoprostone—Gastrointestinal pain—Epirubicin—ovarian cancer	0.000171	0.00111	CcSEcCtD
Dinoprostone—Pain—Doxorubicin—ovarian cancer	0.000165	0.00108	CcSEcCtD
Dinoprostone—Abdominal pain—Epirubicin—ovarian cancer	0.000165	0.00108	CcSEcCtD
Dinoprostone—Body temperature increased—Epirubicin—ovarian cancer	0.000165	0.00108	CcSEcCtD
Dinoprostone—Gastrointestinal pain—Doxorubicin—ovarian cancer	0.000158	0.00103	CcSEcCtD
Dinoprostone—Hypersensitivity—Epirubicin—ovarian cancer	0.000154	0.001	CcSEcCtD
Dinoprostone—Body temperature increased—Doxorubicin—ovarian cancer	0.000153	0.000995	CcSEcCtD
Dinoprostone—Abdominal pain—Doxorubicin—ovarian cancer	0.000153	0.000995	CcSEcCtD
Dinoprostone—Asthenia—Epirubicin—ovarian cancer	0.00015	0.000976	CcSEcCtD
Dinoprostone—Diarrhoea—Epirubicin—ovarian cancer	0.000143	0.00093	CcSEcCtD
Dinoprostone—Hypersensitivity—Doxorubicin—ovarian cancer	0.000142	0.000927	CcSEcCtD
Dinoprostone—Asthenia—Doxorubicin—ovarian cancer	0.000139	0.000903	CcSEcCtD
Dinoprostone—Dizziness—Epirubicin—ovarian cancer	0.000138	0.000899	CcSEcCtD
Dinoprostone—Vomiting—Epirubicin—ovarian cancer	0.000133	0.000865	CcSEcCtD
Dinoprostone—Diarrhoea—Doxorubicin—ovarian cancer	0.000132	0.000861	CcSEcCtD
Dinoprostone—Rash—Epirubicin—ovarian cancer	0.000132	0.000857	CcSEcCtD
Dinoprostone—Dermatitis—Epirubicin—ovarian cancer	0.000132	0.000857	CcSEcCtD
Dinoprostone—Headache—Epirubicin—ovarian cancer	0.000131	0.000852	CcSEcCtD
Dinoprostone—Dizziness—Doxorubicin—ovarian cancer	0.000128	0.000832	CcSEcCtD
Dinoprostone—Nausea—Epirubicin—ovarian cancer	0.000124	0.000808	CcSEcCtD
Dinoprostone—Vomiting—Doxorubicin—ovarian cancer	0.000123	0.0008	CcSEcCtD
Dinoprostone—Rash—Doxorubicin—ovarian cancer	0.000122	0.000793	CcSEcCtD
Dinoprostone—Dermatitis—Doxorubicin—ovarian cancer	0.000122	0.000793	CcSEcCtD
Dinoprostone—Headache—Doxorubicin—ovarian cancer	0.000121	0.000788	CcSEcCtD
Dinoprostone—Nausea—Doxorubicin—ovarian cancer	0.000115	0.000747	CcSEcCtD
Dinoprostone—PTGER1—Signaling by GPCR—MAPK1—ovarian cancer	2.22e-05	0.000133	CbGpPWpGaD
Dinoprostone—PTGER1—Signaling by GPCR—EGFR—ovarian cancer	2.22e-05	0.000133	CbGpPWpGaD
Dinoprostone—PTGIR—Signaling by GPCR—EGFR—ovarian cancer	2.22e-05	0.000133	CbGpPWpGaD
Dinoprostone—PTGER3—Signaling Pathways—MMP9—ovarian cancer	2.22e-05	0.000133	CbGpPWpGaD
Dinoprostone—SLC22A2—Metabolism—SLC2A1—ovarian cancer	2.22e-05	0.000133	CbGpPWpGaD
Dinoprostone—PTGER3—Signaling Pathways—PTEN—ovarian cancer	2.21e-05	0.000132	CbGpPWpGaD
Dinoprostone—ABCC5—Metabolism—PIK3CD—ovarian cancer	2.21e-05	0.000132	CbGpPWpGaD
Dinoprostone—CYP11A1—Metabolism—PIK3CG—ovarian cancer	2.2e-05	0.000132	CbGpPWpGaD
Dinoprostone—SLCO1A2—Metabolism—TYMS—ovarian cancer	2.19e-05	0.000131	CbGpPWpGaD
Dinoprostone—PTGFR—Signaling Pathways—PIK3CD—ovarian cancer	2.19e-05	0.000131	CbGpPWpGaD
Dinoprostone—ABCC4—Hemostasis—KRAS—ovarian cancer	2.18e-05	0.000131	CbGpPWpGaD
Dinoprostone—SLC22A1—Metabolism—FASN—ovarian cancer	2.18e-05	0.00013	CbGpPWpGaD
Dinoprostone—CYP19A1—Metabolism—PPP2R1A—ovarian cancer	2.17e-05	0.00013	CbGpPWpGaD
Dinoprostone—PTGFR—GPCR downstream signaling—PIK3CA—ovarian cancer	2.17e-05	0.00013	CbGpPWpGaD
Dinoprostone—SLC22A2—Neuronal System—HRAS—ovarian cancer	2.17e-05	0.00013	CbGpPWpGaD
Dinoprostone—CYP19A1—Metabolism of lipids and lipoproteins—PTEN—ovarian cancer	2.16e-05	0.00013	CbGpPWpGaD
Dinoprostone—PTGER2—Signaling Pathways—VEGFA—ovarian cancer	2.16e-05	0.000129	CbGpPWpGaD
Dinoprostone—ABCC5—Disease—CDKN1B—ovarian cancer	2.15e-05	0.000129	CbGpPWpGaD
Dinoprostone—PTGER3—Signaling by GPCR—AKT1—ovarian cancer	2.15e-05	0.000129	CbGpPWpGaD
Dinoprostone—PTGFR—Signaling by GPCR—KRAS—ovarian cancer	2.14e-05	0.000129	CbGpPWpGaD
Dinoprostone—PTGIR—Signaling Pathways—PIK3CD—ovarian cancer	2.14e-05	0.000129	CbGpPWpGaD
Dinoprostone—PTGER1—Signaling Pathways—PIK3CD—ovarian cancer	2.14e-05	0.000129	CbGpPWpGaD
Dinoprostone—SLC22A1—Metabolism—SLC5A5—ovarian cancer	2.14e-05	0.000128	CbGpPWpGaD
Dinoprostone—PTGER2—Signaling Pathways—STAT3—ovarian cancer	2.14e-05	0.000128	CbGpPWpGaD
Dinoprostone—PTGER2—Signaling Pathways—NRAS—ovarian cancer	2.13e-05	0.000128	CbGpPWpGaD
Dinoprostone—CYP1A2—Metabolism—CYTB—ovarian cancer	2.13e-05	0.000128	CbGpPWpGaD
Dinoprostone—SLC22A2—Metabolism—CYP1B1—ovarian cancer	2.13e-05	0.000127	CbGpPWpGaD
Dinoprostone—PTGIR—GPCR downstream signaling—PIK3CA—ovarian cancer	2.12e-05	0.000127	CbGpPWpGaD
Dinoprostone—PTGER1—GPCR downstream signaling—PIK3CA—ovarian cancer	2.12e-05	0.000127	CbGpPWpGaD
Dinoprostone—PTGIR—Signaling by GPCR—KRAS—ovarian cancer	2.1e-05	0.000126	CbGpPWpGaD
Dinoprostone—PTGER1—Signaling by GPCR—KRAS—ovarian cancer	2.1e-05	0.000126	CbGpPWpGaD
Dinoprostone—CYP1A2—Metabolism of lipids and lipoproteins—CYP1B1—ovarian cancer	2.08e-05	0.000125	CbGpPWpGaD
Dinoprostone—SLC22A1—Metabolism—SLC2A1—ovarian cancer	2.07e-05	0.000124	CbGpPWpGaD
Dinoprostone—SLCO1B1—Metabolism—PPP2R1A—ovarian cancer	2.06e-05	0.000123	CbGpPWpGaD
Dinoprostone—PTGER4—Signaling Pathways—PIK3CA—ovarian cancer	2.05e-05	0.000123	CbGpPWpGaD
Dinoprostone—SLCO1B1—Metabolism of lipids and lipoproteins—PTEN—ovarian cancer	2.05e-05	0.000123	CbGpPWpGaD
Dinoprostone—PTGER2—Signaling Pathways—MAPK3—ovarian cancer	2.04e-05	0.000122	CbGpPWpGaD
Dinoprostone—ABCC5—Disease—CTNNB1—ovarian cancer	2.03e-05	0.000122	CbGpPWpGaD
Dinoprostone—CYP19A1—Metabolism—ABCB1—ovarian cancer	2.02e-05	0.000121	CbGpPWpGaD
Dinoprostone—SLC22A1—Neuronal System—HRAS—ovarian cancer	2.02e-05	0.000121	CbGpPWpGaD
Dinoprostone—ABCC4—Hemostasis—PIK3CA—ovarian cancer	2e-05	0.00012	CbGpPWpGaD
Dinoprostone—PTGER3—Signaling Pathways—VEGFA—ovarian cancer	1.99e-05	0.000119	CbGpPWpGaD
Dinoprostone—PTGER4—Signaling Pathways—TP53—ovarian cancer	1.99e-05	0.000119	CbGpPWpGaD
Dinoprostone—PTGER2—Signaling Pathways—MYC—ovarian cancer	1.99e-05	0.000119	CbGpPWpGaD
Dinoprostone—ABCC5—Disease—PTEN—ovarian cancer	1.98e-05	0.000119	CbGpPWpGaD
Dinoprostone—CYP19A1—Metabolism—TYMS—ovarian cancer	1.98e-05	0.000119	CbGpPWpGaD
Dinoprostone—SLC22A1—Metabolism—CYP1B1—ovarian cancer	1.98e-05	0.000119	CbGpPWpGaD
Dinoprostone—PTGER3—Signaling Pathways—STAT3—ovarian cancer	1.97e-05	0.000118	CbGpPWpGaD
Dinoprostone—PTGFR—Signaling by GPCR—PIK3CA—ovarian cancer	1.97e-05	0.000118	CbGpPWpGaD
Dinoprostone—PTGER3—Signaling Pathways—NRAS—ovarian cancer	1.97e-05	0.000118	CbGpPWpGaD
Dinoprostone—PTGER2—Signaling Pathways—MAPK1—ovarian cancer	1.94e-05	0.000117	CbGpPWpGaD
Dinoprostone—PTGER2—Signaling Pathways—EGFR—ovarian cancer	1.94e-05	0.000116	CbGpPWpGaD
Dinoprostone—ABCC4—Hemostasis—TP53—ovarian cancer	1.94e-05	0.000116	CbGpPWpGaD
Dinoprostone—PTGFR—Signaling Pathways—ERBB2—ovarian cancer	1.93e-05	0.000116	CbGpPWpGaD
Dinoprostone—CYP11A1—Metabolism—PIK3CD—ovarian cancer	1.93e-05	0.000116	CbGpPWpGaD
Dinoprostone—PTGIR—Signaling by GPCR—PIK3CA—ovarian cancer	1.93e-05	0.000116	CbGpPWpGaD
Dinoprostone—PTGER1—Signaling by GPCR—PIK3CA—ovarian cancer	1.93e-05	0.000116	CbGpPWpGaD
Dinoprostone—ABCC5—Metabolism—PIK3CB—ovarian cancer	1.92e-05	0.000115	CbGpPWpGaD
Dinoprostone—SLCO1B1—Metabolism—ABCB1—ovarian cancer	1.91e-05	0.000114	CbGpPWpGaD
Dinoprostone—PTGFR—Signaling Pathways—PIK3CB—ovarian cancer	1.91e-05	0.000114	CbGpPWpGaD
Dinoprostone—PTGFR—Signaling Pathways—MTOR—ovarian cancer	1.91e-05	0.000114	CbGpPWpGaD
Dinoprostone—PTGER4—Signaling Pathways—HRAS—ovarian cancer	1.9e-05	0.000114	CbGpPWpGaD
Dinoprostone—PTGIR—Signaling Pathways—ERBB2—ovarian cancer	1.89e-05	0.000114	CbGpPWpGaD
Dinoprostone—PTGER1—Signaling Pathways—ERBB2—ovarian cancer	1.89e-05	0.000114	CbGpPWpGaD
Dinoprostone—PTGER3—Signaling Pathways—MAPK3—ovarian cancer	1.89e-05	0.000113	CbGpPWpGaD
Dinoprostone—SLC22A2—Metabolism—PPP2R1A—ovarian cancer	1.89e-05	0.000113	CbGpPWpGaD
Dinoprostone—SLCO1B1—Metabolism—TYMS—ovarian cancer	1.88e-05	0.000112	CbGpPWpGaD
Dinoprostone—PTGER1—Signaling Pathways—PIK3CB—ovarian cancer	1.87e-05	0.000112	CbGpPWpGaD
Dinoprostone—PTGER1—Signaling Pathways—MTOR—ovarian cancer	1.87e-05	0.000112	CbGpPWpGaD
Dinoprostone—PTGIR—Signaling Pathways—MTOR—ovarian cancer	1.87e-05	0.000112	CbGpPWpGaD
Dinoprostone—PTGIR—Signaling Pathways—PIK3CB—ovarian cancer	1.87e-05	0.000112	CbGpPWpGaD
Dinoprostone—CYP1A2—Metabolism—BRIP1—ovarian cancer	1.86e-05	0.000112	CbGpPWpGaD
Dinoprostone—CYP1A2—Metabolism—PPP1CC—ovarian cancer	1.86e-05	0.000112	CbGpPWpGaD
Dinoprostone—ABCC4—Hemostasis—HRAS—ovarian cancer	1.85e-05	0.000111	CbGpPWpGaD
Dinoprostone—HPGDS—Metabolism—AKT1—ovarian cancer	1.85e-05	0.000111	CbGpPWpGaD
Dinoprostone—PTGER2—Signaling Pathways—KRAS—ovarian cancer	1.84e-05	0.00011	CbGpPWpGaD
Dinoprostone—PTGFR—Signaling Pathways—CXCL8—ovarian cancer	1.83e-05	0.00011	CbGpPWpGaD
Dinoprostone—PTGER3—Signaling Pathways—MYC—ovarian cancer	1.83e-05	0.00011	CbGpPWpGaD
Dinoprostone—PTGFR—Signaling by GPCR—HRAS—ovarian cancer	1.82e-05	0.000109	CbGpPWpGaD
Dinoprostone—PTGER4—Signaling Pathways—IL6—ovarian cancer	1.82e-05	0.000109	CbGpPWpGaD
Dinoprostone—PTGER1—Signaling Pathways—CXCL8—ovarian cancer	1.8e-05	0.000108	CbGpPWpGaD
Dinoprostone—PTGIR—Signaling Pathways—CXCL8—ovarian cancer	1.8e-05	0.000108	CbGpPWpGaD
Dinoprostone—PTGER3—Signaling Pathways—MAPK1—ovarian cancer	1.79e-05	0.000108	CbGpPWpGaD
Dinoprostone—PTGER3—Signaling Pathways—EGFR—ovarian cancer	1.79e-05	0.000107	CbGpPWpGaD
Dinoprostone—PTGFR—Signaling Pathways—CDKN1B—ovarian cancer	1.79e-05	0.000107	CbGpPWpGaD
Dinoprostone—PTGIR—Signaling by GPCR—HRAS—ovarian cancer	1.78e-05	0.000107	CbGpPWpGaD
Dinoprostone—PTGER1—Signaling by GPCR—HRAS—ovarian cancer	1.78e-05	0.000107	CbGpPWpGaD
Dinoprostone—ABCC5—Disease—STAT3—ovarian cancer	1.77e-05	0.000106	CbGpPWpGaD
Dinoprostone—PTGFR—GPCR downstream signaling—AKT1—ovarian cancer	1.77e-05	0.000106	CbGpPWpGaD
Dinoprostone—ABCC5—Disease—NRAS—ovarian cancer	1.77e-05	0.000106	CbGpPWpGaD
Dinoprostone—SLCO1A2—Metabolism—CAV1—ovarian cancer	1.77e-05	0.000106	CbGpPWpGaD
Dinoprostone—SLC22A1—Metabolism—PPP2R1A—ovarian cancer	1.76e-05	0.000105	CbGpPWpGaD
Dinoprostone—PTGFR—Signaling Pathways—CASP3—ovarian cancer	1.76e-05	0.000105	CbGpPWpGaD
Dinoprostone—PTGER1—Signaling Pathways—CDKN1B—ovarian cancer	1.75e-05	0.000105	CbGpPWpGaD
Dinoprostone—PTGIR—Signaling Pathways—CDKN1B—ovarian cancer	1.75e-05	0.000105	CbGpPWpGaD
Dinoprostone—PTGFR—Signaling Pathways—IL2—ovarian cancer	1.75e-05	0.000105	CbGpPWpGaD
Dinoprostone—SLC22A2—Metabolism—ABCB1—ovarian cancer	1.75e-05	0.000105	CbGpPWpGaD
Dinoprostone—PTGFR—Signaling by GPCR—IL6—ovarian cancer	1.74e-05	0.000105	CbGpPWpGaD
Dinoprostone—PTGIR—GPCR downstream signaling—AKT1—ovarian cancer	1.74e-05	0.000104	CbGpPWpGaD
Dinoprostone—PTGER1—GPCR downstream signaling—AKT1—ovarian cancer	1.74e-05	0.000104	CbGpPWpGaD
Dinoprostone—SLC22A2—Metabolism—TYMS—ovarian cancer	1.72e-05	0.000103	CbGpPWpGaD
Dinoprostone—PTGIR—Signaling Pathways—CASP3—ovarian cancer	1.72e-05	0.000103	CbGpPWpGaD
Dinoprostone—PTGER1—Signaling Pathways—CASP3—ovarian cancer	1.72e-05	0.000103	CbGpPWpGaD
Dinoprostone—PTGIR—Signaling Pathways—IL2—ovarian cancer	1.72e-05	0.000103	CbGpPWpGaD
Dinoprostone—PTGER1—Signaling Pathways—IL2—ovarian cancer	1.72e-05	0.000103	CbGpPWpGaD
Dinoprostone—PTGFR—Signaling Pathways—CCND1—ovarian cancer	1.71e-05	0.000102	CbGpPWpGaD
Dinoprostone—PTGIR—Signaling by GPCR—IL6—ovarian cancer	1.71e-05	0.000102	CbGpPWpGaD
Dinoprostone—PTGER1—Signaling by GPCR—IL6—ovarian cancer	1.71e-05	0.000102	CbGpPWpGaD
Dinoprostone—ABCC5—Disease—MAPK3—ovarian cancer	1.69e-05	0.000102	CbGpPWpGaD
Dinoprostone—PTGER3—Signaling Pathways—KRAS—ovarian cancer	1.69e-05	0.000102	CbGpPWpGaD
Dinoprostone—PTGFR—Signaling Pathways—CTNNB1—ovarian cancer	1.69e-05	0.000101	CbGpPWpGaD
Dinoprostone—SLCO1A2—Metabolism of lipids and lipoproteins—PIK3CA—ovarian cancer	1.69e-05	0.000101	CbGpPWpGaD
Dinoprostone—PTGER2—Signaling Pathways—PIK3CA—ovarian cancer	1.69e-05	0.000101	CbGpPWpGaD
Dinoprostone—CYP11A1—Metabolism—PIK3CB—ovarian cancer	1.68e-05	0.000101	CbGpPWpGaD
Dinoprostone—PTGER4—Signaling Pathways—AKT1—ovarian cancer	1.68e-05	0.000101	CbGpPWpGaD
Dinoprostone—PTGER1—Signaling Pathways—CCND1—ovarian cancer	1.67e-05	0.0001	CbGpPWpGaD
Dinoprostone—PTGIR—Signaling Pathways—CCND1—ovarian cancer	1.67e-05	0.0001	CbGpPWpGaD
Dinoprostone—ABCC5—Metabolism—PTEN—ovarian cancer	1.66e-05	9.95e-05	CbGpPWpGaD
Dinoprostone—PTGFR—Signaling Pathways—MMP9—ovarian cancer	1.66e-05	9.95e-05	CbGpPWpGaD
Dinoprostone—PTGIR—Signaling Pathways—CTNNB1—ovarian cancer	1.66e-05	9.93e-05	CbGpPWpGaD
Dinoprostone—PTGER1—Signaling Pathways—CTNNB1—ovarian cancer	1.66e-05	9.93e-05	CbGpPWpGaD
Dinoprostone—PTGFR—Signaling Pathways—PTEN—ovarian cancer	1.65e-05	9.89e-05	CbGpPWpGaD
Dinoprostone—ABCC5—Disease—MYC—ovarian cancer	1.65e-05	9.88e-05	CbGpPWpGaD
Dinoprostone—ABCC4—Hemostasis—AKT1—ovarian cancer	1.64e-05	9.81e-05	CbGpPWpGaD
Dinoprostone—PTGER2—Signaling Pathways—TP53—ovarian cancer	1.63e-05	9.78e-05	CbGpPWpGaD
Dinoprostone—SLC22A1—Metabolism—ABCB1—ovarian cancer	1.63e-05	9.78e-05	CbGpPWpGaD
Dinoprostone—PTGIR—Signaling Pathways—MMP9—ovarian cancer	1.62e-05	9.74e-05	CbGpPWpGaD
Dinoprostone—PTGER1—Signaling Pathways—MMP9—ovarian cancer	1.62e-05	9.74e-05	CbGpPWpGaD
Dinoprostone—PTGIR—Signaling Pathways—PTEN—ovarian cancer	1.62e-05	9.68e-05	CbGpPWpGaD
Dinoprostone—PTGER1—Signaling Pathways—PTEN—ovarian cancer	1.62e-05	9.68e-05	CbGpPWpGaD
Dinoprostone—ABCC5—Disease—MAPK1—ovarian cancer	1.61e-05	9.66e-05	CbGpPWpGaD
Dinoprostone—ABCC5—Disease—EGFR—ovarian cancer	1.61e-05	9.66e-05	CbGpPWpGaD
Dinoprostone—SLCO1A2—Metabolism—PIK3CG—ovarian cancer	1.61e-05	9.65e-05	CbGpPWpGaD
Dinoprostone—PTGFR—Signaling by GPCR—AKT1—ovarian cancer	1.61e-05	9.65e-05	CbGpPWpGaD
Dinoprostone—SLC22A1—Metabolism—TYMS—ovarian cancer	1.6e-05	9.6e-05	CbGpPWpGaD
Dinoprostone—CYP19A1—Metabolism—CAV1—ovarian cancer	1.6e-05	9.58e-05	CbGpPWpGaD
Dinoprostone—PTGIR—Signaling by GPCR—AKT1—ovarian cancer	1.58e-05	9.44e-05	CbGpPWpGaD
Dinoprostone—PTGER1—Signaling by GPCR—AKT1—ovarian cancer	1.58e-05	9.44e-05	CbGpPWpGaD
Dinoprostone—PTGER2—Signaling Pathways—HRAS—ovarian cancer	1.56e-05	9.35e-05	CbGpPWpGaD
Dinoprostone—PTGER3—Signaling Pathways—PIK3CA—ovarian cancer	1.56e-05	9.33e-05	CbGpPWpGaD
Dinoprostone—CYP19A1—Metabolism of lipids and lipoproteins—PIK3CA—ovarian cancer	1.53e-05	9.15e-05	CbGpPWpGaD
Dinoprostone—ABCC5—Disease—KRAS—ovarian cancer	1.52e-05	9.13e-05	CbGpPWpGaD
Dinoprostone—SLCO1B1—Metabolism—CAV1—ovarian cancer	1.51e-05	9.06e-05	CbGpPWpGaD
Dinoprostone—PTGER3—Signaling Pathways—TP53—ovarian cancer	1.51e-05	9.03e-05	CbGpPWpGaD
Dinoprostone—PTGER2—Signaling Pathways—IL6—ovarian cancer	1.49e-05	8.95e-05	CbGpPWpGaD
Dinoprostone—PTGFR—Signaling Pathways—VEGFA—ovarian cancer	1.49e-05	8.93e-05	CbGpPWpGaD
Dinoprostone—PTGFR—Signaling Pathways—STAT3—ovarian cancer	1.48e-05	8.84e-05	CbGpPWpGaD
Dinoprostone—PTGFR—Signaling Pathways—NRAS—ovarian cancer	1.47e-05	8.82e-05	CbGpPWpGaD
Dinoprostone—PTGER1—Signaling Pathways—VEGFA—ovarian cancer	1.46e-05	8.74e-05	CbGpPWpGaD
Dinoprostone—PTGIR—Signaling Pathways—VEGFA—ovarian cancer	1.46e-05	8.74e-05	CbGpPWpGaD
Dinoprostone—CYP19A1—Metabolism—PIK3CG—ovarian cancer	1.46e-05	8.72e-05	CbGpPWpGaD
Dinoprostone—CYP11A1—Metabolism—PTEN—ovarian cancer	1.45e-05	8.72e-05	CbGpPWpGaD
Dinoprostone—PTGIR—Signaling Pathways—STAT3—ovarian cancer	1.44e-05	8.66e-05	CbGpPWpGaD
Dinoprostone—PTGER1—Signaling Pathways—STAT3—ovarian cancer	1.44e-05	8.66e-05	CbGpPWpGaD
Dinoprostone—SLCO1B1—Metabolism of lipids and lipoproteins—PIK3CA—ovarian cancer	1.44e-05	8.66e-05	CbGpPWpGaD
Dinoprostone—PTGIR—Signaling Pathways—NRAS—ovarian cancer	1.44e-05	8.64e-05	CbGpPWpGaD
Dinoprostone—PTGER1—Signaling Pathways—NRAS—ovarian cancer	1.44e-05	8.64e-05	CbGpPWpGaD
Dinoprostone—PTGER3—Signaling Pathways—HRAS—ovarian cancer	1.44e-05	8.63e-05	CbGpPWpGaD
Dinoprostone—SLCO1A2—Metabolism—PIK3CD—ovarian cancer	1.42e-05	8.48e-05	CbGpPWpGaD
Dinoprostone—PTGFR—Signaling Pathways—MAPK3—ovarian cancer	1.41e-05	8.45e-05	CbGpPWpGaD
Dinoprostone—ABCC5—Disease—PIK3CA—ovarian cancer	1.4e-05	8.39e-05	CbGpPWpGaD
Dinoprostone—SLC22A2—Metabolism—CAV1—ovarian cancer	1.39e-05	8.3e-05	CbGpPWpGaD
Dinoprostone—PTGER1—Signaling Pathways—MAPK3—ovarian cancer	1.38e-05	8.27e-05	CbGpPWpGaD
Dinoprostone—PTGIR—Signaling Pathways—MAPK3—ovarian cancer	1.38e-05	8.27e-05	CbGpPWpGaD
Dinoprostone—PTGER3—Signaling Pathways—IL6—ovarian cancer	1.38e-05	8.26e-05	CbGpPWpGaD
Dinoprostone—PTGER2—Signaling Pathways—AKT1—ovarian cancer	1.38e-05	8.26e-05	CbGpPWpGaD
Dinoprostone—SLCO1B1—Metabolism—PIK3CG—ovarian cancer	1.38e-05	8.25e-05	CbGpPWpGaD
Dinoprostone—PTGFR—Signaling Pathways—MYC—ovarian cancer	1.37e-05	8.22e-05	CbGpPWpGaD
Dinoprostone—CYP1A2—Metabolism of lipids and lipoproteins—CAV1—ovarian cancer	1.36e-05	8.13e-05	CbGpPWpGaD
Dinoprostone—PTGIR—Signaling Pathways—MYC—ovarian cancer	1.34e-05	8.04e-05	CbGpPWpGaD
Dinoprostone—PTGER1—Signaling Pathways—MYC—ovarian cancer	1.34e-05	8.04e-05	CbGpPWpGaD
Dinoprostone—PTGFR—Signaling Pathways—MAPK1—ovarian cancer	1.34e-05	8.04e-05	CbGpPWpGaD
Dinoprostone—PTGFR—Signaling Pathways—EGFR—ovarian cancer	1.34e-05	8.04e-05	CbGpPWpGaD
Dinoprostone—PTGIR—Signaling Pathways—MAPK1—ovarian cancer	1.31e-05	7.87e-05	CbGpPWpGaD
Dinoprostone—PTGER1—Signaling Pathways—MAPK1—ovarian cancer	1.31e-05	7.87e-05	CbGpPWpGaD
Dinoprostone—PTGER1—Signaling Pathways—EGFR—ovarian cancer	1.31e-05	7.87e-05	CbGpPWpGaD
Dinoprostone—PTGIR—Signaling Pathways—EGFR—ovarian cancer	1.31e-05	7.87e-05	CbGpPWpGaD
Dinoprostone—ABCC5—Disease—HRAS—ovarian cancer	1.29e-05	7.76e-05	CbGpPWpGaD
Dinoprostone—SLC22A1—Metabolism—CAV1—ovarian cancer	1.29e-05	7.74e-05	CbGpPWpGaD
Dinoprostone—CYP19A1—Metabolism—PIK3CD—ovarian cancer	1.28e-05	7.67e-05	CbGpPWpGaD
Dinoprostone—PTGER3—Signaling Pathways—AKT1—ovarian cancer	1.27e-05	7.62e-05	CbGpPWpGaD
Dinoprostone—PTGFR—Signaling Pathways—KRAS—ovarian cancer	1.27e-05	7.59e-05	CbGpPWpGaD
Dinoprostone—SLC22A2—Metabolism—PIK3CG—ovarian cancer	1.26e-05	7.56e-05	CbGpPWpGaD
Dinoprostone—CYP1A2—Metabolism—YAP1—ovarian cancer	1.25e-05	7.48e-05	CbGpPWpGaD
Dinoprostone—PTGIR—Signaling Pathways—KRAS—ovarian cancer	1.24e-05	7.43e-05	CbGpPWpGaD
Dinoprostone—PTGER1—Signaling Pathways—KRAS—ovarian cancer	1.24e-05	7.43e-05	CbGpPWpGaD
Dinoprostone—ABCC5—Disease—IL6—ovarian cancer	1.24e-05	7.43e-05	CbGpPWpGaD
Dinoprostone—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CG—ovarian cancer	1.24e-05	7.41e-05	CbGpPWpGaD
Dinoprostone—SLCO1A2—Metabolism—PIK3CB—ovarian cancer	1.23e-05	7.4e-05	CbGpPWpGaD
Dinoprostone—SLCO1B1—Metabolism—PIK3CD—ovarian cancer	1.21e-05	7.26e-05	CbGpPWpGaD
Dinoprostone—SLC22A1—Metabolism—PIK3CG—ovarian cancer	1.18e-05	7.05e-05	CbGpPWpGaD
Dinoprostone—ABCC5—Metabolism—PIK3CA—ovarian cancer	1.17e-05	7.02e-05	CbGpPWpGaD
Dinoprostone—PTGFR—Signaling Pathways—PIK3CA—ovarian cancer	1.16e-05	6.98e-05	CbGpPWpGaD
Dinoprostone—ABCC5—Disease—AKT1—ovarian cancer	1.14e-05	6.85e-05	CbGpPWpGaD
Dinoprostone—PTGER1—Signaling Pathways—PIK3CA—ovarian cancer	1.14e-05	6.83e-05	CbGpPWpGaD
Dinoprostone—PTGIR—Signaling Pathways—PIK3CA—ovarian cancer	1.14e-05	6.83e-05	CbGpPWpGaD
Dinoprostone—PTGFR—Signaling Pathways—TP53—ovarian cancer	1.13e-05	6.75e-05	CbGpPWpGaD
Dinoprostone—CYP19A1—Metabolism—PIK3CB—ovarian cancer	1.12e-05	6.68e-05	CbGpPWpGaD
Dinoprostone—SLC22A2—Metabolism—PIK3CD—ovarian cancer	1.11e-05	6.65e-05	CbGpPWpGaD
Dinoprostone—PTGIR—Signaling Pathways—TP53—ovarian cancer	1.1e-05	6.61e-05	CbGpPWpGaD
Dinoprostone—PTGER1—Signaling Pathways—TP53—ovarian cancer	1.1e-05	6.61e-05	CbGpPWpGaD
Dinoprostone—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CD—ovarian cancer	1.09e-05	6.51e-05	CbGpPWpGaD
Dinoprostone—PTGFR—Signaling Pathways—HRAS—ovarian cancer	1.08e-05	6.45e-05	CbGpPWpGaD
Dinoprostone—SLCO1A2—Metabolism—PTEN—ovarian cancer	1.07e-05	6.39e-05	CbGpPWpGaD
Dinoprostone—SLCO1B1—Metabolism—PIK3CB—ovarian cancer	1.06e-05	6.32e-05	CbGpPWpGaD
Dinoprostone—PTGIR—Signaling Pathways—HRAS—ovarian cancer	1.05e-05	6.32e-05	CbGpPWpGaD
Dinoprostone—PTGER1—Signaling Pathways—HRAS—ovarian cancer	1.05e-05	6.32e-05	CbGpPWpGaD
Dinoprostone—SLC22A1—Metabolism—PIK3CD—ovarian cancer	1.03e-05	6.2e-05	CbGpPWpGaD
Dinoprostone—PTGFR—Signaling Pathways—IL6—ovarian cancer	1.03e-05	6.18e-05	CbGpPWpGaD
Dinoprostone—CYP11A1—Metabolism—PIK3CA—ovarian cancer	1.03e-05	6.15e-05	CbGpPWpGaD
Dinoprostone—CYP1A2—Metabolism—FASN—ovarian cancer	1.02e-05	6.1e-05	CbGpPWpGaD
Dinoprostone—PTGIR—Signaling Pathways—IL6—ovarian cancer	1.01e-05	6.05e-05	CbGpPWpGaD
Dinoprostone—PTGER1—Signaling Pathways—IL6—ovarian cancer	1.01e-05	6.05e-05	CbGpPWpGaD
Dinoprostone—CYP1A2—Metabolism—SLC5A5—ovarian cancer	1e-05	6e-05	CbGpPWpGaD
Dinoprostone—CYP1A2—Metabolism—SLC2A1—ovarian cancer	9.67e-06	5.8e-05	CbGpPWpGaD
Dinoprostone—SLC22A2—Metabolism—PIK3CB—ovarian cancer	9.67e-06	5.8e-05	CbGpPWpGaD
Dinoprostone—CYP19A1—Metabolism—PTEN—ovarian cancer	9.64e-06	5.78e-05	CbGpPWpGaD
Dinoprostone—ABCC5—Metabolism—AKT1—ovarian cancer	9.57e-06	5.74e-05	CbGpPWpGaD
Dinoprostone—PTGFR—Signaling Pathways—AKT1—ovarian cancer	9.51e-06	5.7e-05	CbGpPWpGaD
Dinoprostone—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CB—ovarian cancer	9.47e-06	5.68e-05	CbGpPWpGaD
Dinoprostone—PTGER1—Signaling Pathways—AKT1—ovarian cancer	9.31e-06	5.58e-05	CbGpPWpGaD
Dinoprostone—PTGIR—Signaling Pathways—AKT1—ovarian cancer	9.31e-06	5.58e-05	CbGpPWpGaD
Dinoprostone—CYP1A2—Metabolism—CYP1B1—ovarian cancer	9.27e-06	5.56e-05	CbGpPWpGaD
Dinoprostone—SLCO1B1—Metabolism—PTEN—ovarian cancer	9.12e-06	5.46e-05	CbGpPWpGaD
Dinoprostone—SLC22A1—Metabolism—PIK3CB—ovarian cancer	9.01e-06	5.4e-05	CbGpPWpGaD
Dinoprostone—CYP11A1—Metabolism—AKT1—ovarian cancer	8.38e-06	5.02e-05	CbGpPWpGaD
Dinoprostone—SLC22A2—Metabolism—PTEN—ovarian cancer	8.36e-06	5.01e-05	CbGpPWpGaD
Dinoprostone—CYP1A2—Metabolism—PPP2R1A—ovarian cancer	8.22e-06	4.93e-05	CbGpPWpGaD
Dinoprostone—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—ovarian cancer	8.18e-06	4.9e-05	CbGpPWpGaD
Dinoprostone—SLC22A1—Metabolism—PTEN—ovarian cancer	7.79e-06	4.67e-05	CbGpPWpGaD
Dinoprostone—CYP1A2—Metabolism—ABCB1—ovarian cancer	7.63e-06	4.58e-05	CbGpPWpGaD
Dinoprostone—SLCO1A2—Metabolism—PIK3CA—ovarian cancer	7.52e-06	4.51e-05	CbGpPWpGaD
Dinoprostone—CYP1A2—Metabolism—TYMS—ovarian cancer	7.5e-06	4.49e-05	CbGpPWpGaD
Dinoprostone—CYP19A1—Metabolism—PIK3CA—ovarian cancer	6.8e-06	4.07e-05	CbGpPWpGaD
Dinoprostone—SLCO1B1—Metabolism—PIK3CA—ovarian cancer	6.43e-06	3.86e-05	CbGpPWpGaD
Dinoprostone—SLCO1A2—Metabolism—AKT1—ovarian cancer	6.14e-06	3.68e-05	CbGpPWpGaD
Dinoprostone—CYP1A2—Metabolism—CAV1—ovarian cancer	6.04e-06	3.62e-05	CbGpPWpGaD
Dinoprostone—SLC22A2—Metabolism—PIK3CA—ovarian cancer	5.89e-06	3.53e-05	CbGpPWpGaD
Dinoprostone—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—ovarian cancer	5.77e-06	3.46e-05	CbGpPWpGaD
Dinoprostone—CYP19A1—Metabolism—AKT1—ovarian cancer	5.55e-06	3.33e-05	CbGpPWpGaD
Dinoprostone—CYP1A2—Metabolism—PIK3CG—ovarian cancer	5.5e-06	3.3e-05	CbGpPWpGaD
Dinoprostone—SLC22A1—Metabolism—PIK3CA—ovarian cancer	5.49e-06	3.29e-05	CbGpPWpGaD
Dinoprostone—SLCO1B1—Metabolism—AKT1—ovarian cancer	5.25e-06	3.15e-05	CbGpPWpGaD
Dinoprostone—CYP1A2—Metabolism—PIK3CD—ovarian cancer	4.84e-06	2.9e-05	CbGpPWpGaD
Dinoprostone—SLC22A2—Metabolism—AKT1—ovarian cancer	4.82e-06	2.89e-05	CbGpPWpGaD
Dinoprostone—SLC22A1—Metabolism—AKT1—ovarian cancer	4.49e-06	2.69e-05	CbGpPWpGaD
Dinoprostone—CYP1A2—Metabolism—PIK3CB—ovarian cancer	4.22e-06	2.53e-05	CbGpPWpGaD
Dinoprostone—CYP1A2—Metabolism—PTEN—ovarian cancer	3.64e-06	2.18e-05	CbGpPWpGaD
Dinoprostone—CYP1A2—Metabolism—PIK3CA—ovarian cancer	2.57e-06	1.54e-05	CbGpPWpGaD
Dinoprostone—CYP1A2—Metabolism—AKT1—ovarian cancer	2.1e-06	1.26e-05	CbGpPWpGaD
